Argentum Pharmaceuticals recently announced that it, along with its manufacturing partner KVK Tech, has been granted a petition for inter partes review (IPR) against all challenged claims of the sole patent that covers Alcon’s PAZEO by the U.S. Patent & Trademark Office (PTO). Read More »
With only the slightest of increases, Medicare recently announced that the average monthly cost for a Medicare Part D prescription drug plan in 2017 is projected to remain reasonably stable at approximately $34. Read More »
Ardelyx Inc. recently announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its composition of matter patent application for RDX227675. Read More »
Galmed Pharmaceuticals has announced that Professor Ran Oren, M.D., has been named its Chief Medical Officer (CMO). Read More »
Pfizer Inc. recently announced that its third Phase III study of XELJANZ (tofacitinib citrate), Oral Clinical Trials for tofacitinib in ulcerative colitis (OCTAVE) Sustain, has turned in positive result Read More »
The Drug Enforcement Administration’s (DEA) Liaison and Policy Section has asked that the National Association of Chain Drug Stores (NACDS) to share information regarding its Pharmacy Diversion Awareness Conferences that will be held in August with member companies. Read More »
Partnership makes NARCAN Nasal Spray more affordable at CVS Pharmacies. Read More »
Pfizer Inc. recently published the findings from two pivotal Phase III studies of crisaborole topical ointment 2 percent, formerly known as AN2728. Read More »
The U.S. Food and Drug Administration (FDA) has approved Silvergate Pharmaceuticals’ Qbrelis Oral Solution, the first Lisinopril oral solution that has been approved by the agency. Read More »
Rare disease leads to severe disability; no approved therapy yet. Read More »
Board increases to 12 members; 11 are independent directors. Read More »
Cytokinetics, Inc. and Astellas Pharma, Inc. have announced the expansion of their collaboration in skeletal muscle activators for the inclusion of amyotrophic lateral sclerosis (ALS). Read More »
Galmed Pharmaceuticals Ltd. and SAMIL Pharm. Co.recently announced that a license agreement has been put into place for an exclusive, royalty-bearing license for Aramchol and its commercialization. Read More »
Jostling among hospitals, pharmacies, doctors, and third-party payers over the delivery of specialty cancer drugs is likely to intensify, according to experts observing the already fast shifting field of oncology treatment channeling. Read More »
Approved for use with diet and exercise; also approved as a combination therapy with other diabetes medications and insulin. Read More »
Cancer vaccine WO-12 to be developed by Pfizer and Western Oncolytics. Read More »
Franchise partnership agreement signed with Emart last week. Read More »
First potential treatment for CLN2 on fast track for development. Read More »
Clear side Biomedical Inc. recently released the reports from its Phase II TANZANITE clinical trial showing top-line data from the study. Read More »
Cynosure recently announced that SculpSure has received marketing approval from the Korean Ministry of Food and Drug Safety (MFDS) for non-invasive lipolysis of the abdomen and flanks. Read More »
Alerts Sign-up
